- Home
- CCEL vs TVRD Comparison
CCEL vs TVRD Comparison
Compare CCEL & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CCEL | TVRD |
|---|---|---|
| Founded | 1989 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Managed Health Care | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.7M | 34.1M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | CCEL | TVRD |
|---|---|---|
| Price | $3.37 | $3.90 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 7 |
| Target Price | N/A | ★ $51.67 |
| AVG Volume (30 Days) | 12.5K | ★ 50.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 4.45% | N/A |
| EPS Growth | ★ 104.39 | N/A |
| EPS | ★ 0.17 | N/A |
| Revenue | ★ $25,384,279.00 | N/A |
| Revenue This Year | $0.30 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $19.82 | ★ N/A |
| Revenue Growth | ★ 9.76 | N/A |
| 52 Week Low | $3.10 | $3.50 |
| 52 Week High | $7.91 | $43.65 |
Technical Indicators
Market Signals| Indicator | CCEL | TVRD |
|---|---|---|
| Relative Strength Index (RSI) | 49.35 | 53.92 |
| Support Level | $3.33 | $3.81 |
| Resistance Level | $3.57 | $4.45 |
| Average True Range (ATR) | 0.14 | 0.26 |
| MACD | 0.01 | 0.05 |
| Stochastic Oscillator | 68.87 | 96.36 |
Price Performance
Historical ComparisonAbout CCEL Cryo-Cell International Inc.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.
About TVRD Tvardi Therapeutics Inc.
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.